Managing the Care of Patients With Renal Cell Carcinoma During the COVID-19 Pandemic: Advice from Nazy Zomorodian, RNC, MSN, CUNP, CCRC

Nazy Zomorodian, RNC, MSN, CUNP, CCRC.
At the Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit in Los Angeles, California, Oncology Data Advisor spoke with Nazy Zomorodian, NP, a nurse practitioner in the Department of Urology at the University of California Los Angeles (UCLA) Medical Center, about strategies for optimizing patient experiences during renal cell carcinoma treatment. Ms. Zomorodian discusses the challenges of treating patients with renal cell carcinoma, particularly during the COVID-19 pandemic, and shares strategies for promoting adherence and optimizing treatment outcomes.
Continue reading

FDA Approves Gallium 68 PSMA-11 for PET Imaging in Prostate Cancer

The FDA has approved gallium (Ga) 68 PSMA-11, a radioactive diagnostic agent, for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in patients with prostate cancer. Ga 68 PSMA-11 is indicated for patients with suspected prostate cancer metastasis who are eligible for surgery or radiation therapy and for patients who have suspected recurrence based on elevated levels of prostate-specific antigen (PSA). The first drug to be approved specifica...
Continue reading

Optimizing Prostate Cancer Detection: Interview With Johannes Czernin, MD

There is a discrepancy in guideline recommendations regarding prostate cancer detection; National Comprehensive Cancer Network (NCCN) guidelines recommend using 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localization after radical prostatectomy as opposed to European Association of Urology (EAU) guidelines, which recommend prostate-specific membrane antigen (PSMA) PET-CT. Jeremie Calais, MD, Johannes Czernin, MD, and colleagues compared using 18F-fluciclovine PET-CT versu...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.